BIOTECHNOLOGY-HEADER

RUS

      

ENG

Vol 33(2017) N 5 p. 45-60; DOI 10.21519/0234-2758-2017-33-5-45-60
N.I. Mikshis*, P.Yu. Popova, A.P. Semakova, O.M. Kudryavtseva, S.A. Bugorkova, and A.L. Kravtsov

Effect of Antigens Obtained from Bacillus anthracis 55ΔТПА 1Spo- Recombinant Strain on Organs and Tissues of Immunized Animals

The Russian Research Anti-Plague Institute Microbe, Federal Service for Surveillance in the Sphere of Consumers Rights Protection and Human Welfare (Rospotrebnadzor), 410005 Saratov, Russia

*rusrapi@microbe.ru
Received - 13.03.2017; Accepted - 12.04.2017

References

A recombinant B. anthracis strain 55ΔTPA-1Spo- has been used for the development and evaluation of a new method for the combined production of immunogenic anthrax antigens, the protective antigen and S-layer protein EA1, components of the anthrax vaccine. The technique includes the seed culture preparation, growth on a liquid medium without antibiotic, sterilization filtration, concentration, diafiltration, and chromatographic purification on various carriers, and provides the high yield of both target products. It was demonstrated that the purified antigens, singly or in combination, do not have toxic effect on organs and tissues of vaccinated test animals in amounts a few times superior to immunizing doses. Insignificant changes detected by the histological examination reflected the adaptation-compensatory reactions of the macroorganism tending to normalization. The response of immune-competent organs corresponded to moderate manifestations of immunogenesis. It was established that the addition of the EA1 protein to the recombinant protective antigen leads to the increase in the expression of genes that determine the innate immunity TLR. The immunization of test animals with the combined preparation as compared to the single rPA resulted in more expressed immunobiological alterations in lymphoid organs.

Bacillus anthracis, anthrax, anthrax vaccines, recombinant protective antigen.



GOSNIIGENETIKA-FOOTER GOSNIIGENETIKA